AndroGel and Levothyroxine Interaction: What You Need to Know

AndroGel is a brand of topical testosterone gel (1% or 1.62%), a controlled substance used to treat male hypogonadism. Levothyroxine is synthetic thyroxine (T4), used to treat hypothyroidism, sold under brand names including Synthroid and as generic tablets. These two drugs are commonly prescribed together in men with both conditions, and this page addresses that specific combination, not testosterone paired with other thyroid medications such as liothyronine or desiccated thyroid.

Direct answer: AndroGel and levothyroxine are not contraindicated together and there is no absorption conflict, since one is applied to the skin and the other is swallowed. The interaction that matters is pharmacodynamic: exogenous testosterone can lower thyroxine-binding globulin (TBG), which lowers total T4. In a man with an intact thyroid this is compensated automatically; in a man dependent on a fixed levothyroxine dose, it can mean his existing dose becomes insufficient, showing up as a rising TSH weeks after starting or increasing testosterone. This is a monitoring issue, not a reason to avoid either drug.

Why this pairing needs attention

Hypogonadism and hypothyroidism both increase in prevalence with age, and it is not unusual for the same man to be managed for both. The clinical concern is narrow but real: a patient who was previously stable on levothyroxine may become subclinically or clinically hypothyroid after starting testosterone therapy if no one rechecks his labs. This is easy to miss because the patient may attribute new fatigue to "TRT not working" rather than an undertreated thyroid.

What the mechanism is, and what it is not

The interaction is not a cytochrome P450 or P-glycoprotein drug-drug interaction, and testosterone does not measurably alter levothyroxine absorption from the gut. The mechanism runs through binding proteins. Androgens are understood to reduce hepatic synthesis and increase clearance of TBG, the main carrier protein for circulating T4. This is a well-established property of the androgen drug class in endocrinology, referenced in FDA labeling. AndroGel's own prescribing information states that androgens may decrease thyroxine-binding globulin concentration, resulting in decreased total T4 serum concentration and increased resin uptake of T3 and T4 (per AndroGel's FDA-approved prescribing information; confirm current label version before citing to a patient).

In a man with a working thyroid gland, a drop in TBG triggers a brief compensatory rise in TSH, and the thyroid produces more T4 until free T4 normalizes. A man on fixed-dose levothyroxine has no gland left to compensate with (this is especially true after thyroidectomy or radioactive iodine ablation). If TBG falls, total T4 falls, and depending on how much protein-bound reserve existed, free T4 can fall too, with TSH rising in response.

What is established, what is plausible, and what is not proven

Evidence-status assessment: testosterone (AndroGel) plus levothyroxine

This table is the core of the page: it separates what pharmacology reliably predicts from what would require a dedicated trial to prove, and flags where a prior version of this content overstated precision.

Practical monitoring approach

Because the direction of the interaction is predictable even though the magnitude is not well quantified in men, a conservative monitoring approach is reasonable rather than a fixed formula:

• Get a baseline TSH (and free T4 if already ordered) before starting AndroGel in anyone on levothyroxine.
• Recheck TSH roughly 4 to 8 weeks after starting testosterone or after any dose change, since testosterone gel typically reaches steady state within a few weeks and TSH takes time to reflect a new hormone equilibrium. This interval is a reasonable clinical convention, not a number drawn from a verified trial specific to this drug pair.
• If TSH rises above the patient's target range, the levothyroxine dose is adjusted based on that lab result, not on a preset percentage. Available tablet strengths (for example, 88, 100, 112, 125 mcg) allow small stepwise changes.
• Recheck again 6 to 8 weeks after any levothyroxine adjustment.
• If testosterone is stopped, TBG is expected to rise again, which can make the prior levothyroxine dose too high; recheck TSH 6 to 8 weeks after stopping and reduce the dose if TSH falls below the patient's target.

Men who are most likely to notice this interaction clinically are those with no residual thyroid function (post-thyroidectomy or post-radioactive-iodine ablation), because they have zero compensatory capacity. Men with a partially functioning thyroid and subclinical hypothyroidism on low-dose levothyroxine may also be more sensitive to a small TBG shift.

Absorption timing

There is no pharmacokinetic reason to separate AndroGel and levothyroxine by time of day, since one is transdermal and the other is oral. Standard levothyroxine guidance still applies regardless of testosterone use: it is generally taken on an empty stomach, well separated from calcium, iron, and coffee, per levothyroxine product labeling (confirm current label version). A practical routine is levothyroxine on waking and AndroGel applied after a shower, once skin is dry, allowing the recommended drying time before clothing contact or swimming.

Cardiovascular and other safety context

AndroGel's labeling carries safety information related to cardiovascular risk that a prescriber should discuss directly with the patient; this is separate from the thyroid-binding interaction discussed here and should not be conflated with it. If a large randomized cardiovascular safety trial of testosterone replacement is being cited to a patient, the specific trial name, population, and result should be confirmed against the primary publication rather than repeated from memory, since exact trial claims are easy to misstate.

Testosterone therapy is also reported to interact, through separate mechanisms, with warfarin (increased anticoagulant sensitivity, requiring INR monitoring) and with insulin or sulfonylureas (potential improvement in insulin sensitivity, requiring closer glucose monitoring). These are pharmacodynamic effects distinct from the thyroid-binding-protein mechanism above and are not detailed further on this page.

When to seek care sooner

New or worsening fatigue, unexplained weight gain, constipation, cold intolerance, dry skin, or mental sluggishness in the months after starting or adjusting AndroGel, in someone already on levothyroxine, is a reason to contact the prescribing clinician for a thyroid recheck rather than waiting for the next scheduled visit. Chest pain, irregular heartbeat, or symptoms of a possible blood clot warrant urgent evaluation regardless of thyroid status.

What this page cannot tell you

This page cannot tell an individual patient what their levothyroxine dose should be, whether their TSH change is due to testosterone versus another cause, or how their specific cardiovascular risk factors interact with testosterone therapy. Those require a clinician reviewing the person's actual labs, history, and current medication list.